Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-04-25
2006-04-25
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100, C530S387300, C530S388220, C536S023530
Reexamination Certificate
active
07033589
ABSTRACT:
Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
REFERENCES:
patent: 4940782 (1990-07-01), Rup et al.
patent: 4975369 (1990-12-01), Beavers et al.
patent: 5348876 (1994-09-01), Michaelson et al.
patent: 5543144 (1996-08-01), Chang et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5635600 (1997-06-01), Fanger et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5648267 (1997-07-01), Reff
patent: 5658570 (1997-08-01), Newman et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5811524 (1998-09-01), Brams et al.
patent: 6001358 (1999-12-01), Black et al.
patent: 6011138 (2000-01-01), Reff et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: WO 87/07302 (1987-12-01), None
patent: WO 88/06891 (1988-09-01), None
patent: WO 89/00138 (1989-01-01), None
patent: WO 92/17207 (1992-10-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 96/12741 (1996-05-01), None
patent: WO 96/12742 (1996-05-01), None
The Merck Manual 16th Edition. 1992. Berkow, R., ed Rahway, NJ, pp. 1305-1312 and 1334-1338.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” 1994,The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser Boston, pp. 490-495.
Boulet et al., “Inhibitory Effects of an Anti-Ige Antibody E25 on Allergen-induced Early Asthmatic Response,”Am J Respir Crit Care Med, (1997) 155:1835-44.
Casale et al., “Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis,”J Allergy Clin Immunol, (1997), 100:110-120.
Coyle et al., “Central Role of Immunoglobulin (Ig) E in the Induction of Lung Eosinophil Infltration and T Helper 2 Cell Cytokine Production: Inhibition by a Non-anaphylactogenic Anti-IgE Antibody,”J Exp Med, (1996), 183:1303-1310.
Fahy et al., “The Effect of an Anti-IgE Monoclonal Antibody on the Early-and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects,”Am J Respir Crit Care Med, (1997), 155:1828-34.
Ohashi et al., “Immunotherapy Affects the Seasonal Increase in Specific IgE and Interleukin-4 in Serum of Patients with Seasonal Allergic Rhinitis,”Scan J Immunol, (1997), 46(1):67-77.
Ohashi et al., “Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis,”Annals of Allergy, Asthma, and Immunol, (1997), 79:213-220.
Ohashi et al., “Ten-Year Follow-Up Study of Allergen-Specific Immunoglobulin E and Immunoglobulin G4, Soluble Interlcukin-2 Receptor, Interleukin-4, Soluble Intercellular Adhesion Molecule-1 and Soluble Vascular Cell Adhesion Molecule-1 in Serum of Patients on Immunotherapy for Perennial Allergic Rhinitis,”Scand J Immunol, (1998), 47:167-178.
Peebles et al., “Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation,”J Allergy Clin Immunol, (1998), 101:265-273.
Pullerits et al., “An intranasal glucocorticoid inhibits the increase of specific IgE initiated during birch pollen season,”J Allergy Clin Immunol, (1997), 100:601-605.
Reff et al., “Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20,”Blood, (1994), 83:435-445.
Ward E.S. and Ghetie V., “The effector functions of immunoglobulins: implications for therapy,” 1995,Therapeutic Immunology, 2:77-94.
Bettler et al., Binding Site Foε IgE of the Human Lymphocyte Low-Affinity For Receptor (FCεRII/CD23) is Confined to the Domain Homologous With Animal Lectins,Proc. Natl. Acad. Sci., USA, vol. 86, pp. 7118-7112, Sep. 1989.
Bonnefoy et al., Inhibition of Human Interleukin 4-Induced IgE Synthesis by a Subset of Anti-CD23/FceRII Monoclonal Antibodies,Eur. J. Immunol., vol. 20:139-144, 1990.
Rector et al., “Detection and characterization of monoclonal antibodies specific to IgE receptors on human lymphocytes by flow cytometry”, Immunol., 55: 481-488 (1985).
Suemura et al., “Monoclonal anti-Fc epsilon receptor antibodies with different specificities and studies on the expression of Fc epsilon receptors on human B and T cells”, J. Immunol., 137: 1214-1220 (1986).
Noro et al., “Monoclonal antibody (H107) inhibiting IgE binding to Fc epsilon R(+) human lymphocytes”, J. Immunol., 137: 1258-1263 (1986).
Yu et al., “Negative feedback regulation of IgE synthesis by murine CD23”, Nature 369: 753-756 (1994).
Bonnefoy et al., “Regulation of IgE synthesis by CD23/CD21 interaction”, Int. Arch. Allergy Immunol., 107:40-42 (1995).
Grosjean et al., “CD23/CD21 interaction is required for presentation of soluble protein antigen by lymphoblastoid B cell lines to specific CD4+ T cell clones”, Eur. J. Immunol., 24:2982-2988 (1994).
Pene et al., “Interleukin 5 enhances interleukin 4-induced IgE production by normal human B cells. The role of soluble CD23 antigen”, Eur. J. Immunol., 18:929-935 (1988).
Saxon et al., “Soluble CD23 containing B cell supernatants induce IgE from peripheral blood B-lymphocytes and costimulate with interleukin-4 in induction of IgE”, J. Allergy Clin. Immunol., 86 (3 pt 1) 333-344 (1990).
Hassner and Saxon. “Isotype-specific human suppressor T cells for IgE synthesis activated by IgE-anti-IgE immune complexes”. J. Immunol., 132:2844 (1984).
Carroll et al., “Mouse x human heterohybridomas as fusion partners with human B cell tumors”, J. Immunol. Method, 89: 61 (1986).
Boerner et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes”, J. Immonol., 147: 86 (1991).
Luo et al., “Cross-linking of CD23 antigen by its natural ligand (IgE) or by anti-CD23 antibody prevents B lymphocyte proliferation and differentiation” J. Immunol., 146(7):2122-9 (1991).
Groves et al., “Production of an ovine monoclonal antibody to testosterone by an interspecies fusion”, Hybridoma, vol. 6(1):71 (1987).
Robbins, “Diseases of Immunity,” Pathologic Basis of Disease, pp. 197-199 (1994).
Seaver, “Monoclonal Antibodies in Industry: More Difficult than Oringally Thought,” Genetic Engineering, 14(14): 10 and 21 (1994).
Haak-Frendscho et al., “Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo”, Immunology, 82:306 (1994).
Delespesse et al., “Human IgE-binding factors”, Immunology Today, 10:159, (1989).
Durum and Oppenheim, “Proinflammatory Cytokines and Immunity,” Fundamental Immunology, 3rd Edition, Chapter 21, p. 801-835, Raven Press Ltd. (1993).
Vercelli et al., “Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens”, J. Exp. Med., 169:1295 (Apr. 1989).
Presta et al., “Humanization of an antibody directed against IgE”, J. Immunology, 151(5):2623 (Sep. 1993).
Strike et al., “Production of human-human hybridomas secreting antibody to sheep erythrocytes after in vitro immunization”, J. Immunol., 132(4): 1798 (Apr. 1984).
Cruse et al., Illustrated Dictionary of Immunology, CRC Press, p. 69 (1995).
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy”, Nature, 337-525 (Feb. 1989).
Bourget et al., Eur. J. Immunol., 12(7):1872-76 (1995).
Bonnefoy et al., “A new role for CD23 in inflammation”, Immunol. Today, 17(9):418-20 (1996).
Urlaub et al., Somatic Cell and Mol. Genetics, 12(6):555-66 (1986).
Co et al., “Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys”, Can. Res., 56:1118-25 (1996).
Ono et al., “Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling”
Kloetzer William S.
Nakamura Takehiko
Reff Mitchell E.
Biogen Idec MA Inc.
Chan Christina
Huynh Phuong
Pillsbury & Winthrop LLP
LandOfFree
γ-1 anti-human CD23 monoclonal antibodies and use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with γ-1 anti-human CD23 monoclonal antibodies and use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and γ-1 anti-human CD23 monoclonal antibodies and use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3552512